New Biocatalyst for Enantioselective Synthesis

Information

  • Research Project
  • 6520177
  • ApplicationId
    6520177
  • Core Project Number
    R44GM060830
  • Full Project Number
    5R44GM060830-03
  • Serial Number
    60830
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/2000 - 24 years ago
  • Project End Date
    3/31/2004 - 20 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    4/1/2002 - 22 years ago
  • Budget End Date
    3/31/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    3
  • Suffix
  • Award Notice Date
    3/28/2002 - 22 years ago

New Biocatalyst for Enantioselective Synthesis

DESCRIPTION: (Applicant's abstract) The development of enzyme biocatalysts that are reusable and able to work in heterogeneous reaction systems is the focus of this proposal. A reversibly soluble polymer is to be attached to the enzymes. Consequently, the biocatalyst can be precipitated without enzyme denaturation after product separation. Later the biocatalyst can be dissolved again in a suspension of the starting materials at the initial conditions. Therefore, these biocatalysts acquire the advantages of free enzymes (high activity in heterogeneous systems) and of immobilized enzymes (the possibility of a reuse). Biocatalysis is underutilized in industry due to the industry requirement that the biocatalyst should be reusable and the reaction has a high throughput. Solubility of the compounds in limited and this necessitates running the reaction in heterogeneous suspension of the starting materials and the products. However, today all biocatalysts on the market either cannot be reused or do not work in heterogeneous systems. Feasibility of the idea was demonstrated on during Phase I. Phase II focuses on the optimization of the process using the enzymes of industrial interests. These biocatalysts will be marketed to pharmaceutical companies and used to manufacture chiral pharmaceuticals. In 2000, the market for such biocatalysts is about $200 million. PROPOSED COMMERCIAL APPLICATION: The enzyme biocatalysts described in proposal are unique because they combine advantages of free and immobilized enzymes. There are no biocatalysts of this kind commercially available and an enormous commercial potential exists because most drugs are developed in a single enantiomer form. Sales of the reversibly soluble biocatalyst for a production of just one drug can generate up to several million US dollars per year.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    349599
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:349599\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    POLIUM TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    083161021
  • Organization City
    HOFFMAN ESTATES
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    60195
  • Organization District
    UNITED STATES